Table 3.
First post-nivolumab treatment in 492 patients enrolled in the IFCT 1502-CLINIVO study
| Systemic treatment | n = 450 (91.5%) | ||
| Single-agent chemotherapy | n = 273 (61%) | Docetaxel | 77 (17%) |
| Gemcitabine | 79 (18%) | ||
| Paclitacel ± bevacizumab | 50 (11%) | ||
| Vinorelbine | 39 (9%) | ||
| Pemetrexed | 26 (6%) | ||
| Other | 2 (1%) | ||
| Platin-based doublet | n = 47 (10%) | Platin–paclitaxel | 25 (6%) |
| Other | 22 (5%) | ||
| Targeted therapy | n = 78 (17%) | Erlotinib | 59 (13%) |
| Other | 19 (4%) | ||
| Immunotherapy rechallenge | n = 37 (8%) | Nivolumab | 29 (6%) |
| Other | 8 (2%) | ||
| Other/unknown systemic treatment | n = 15 (3%) | ||
| Radiotherapy | n = 118 (24%) | ||
| Surgery | n = 18 (4%) | ||
IFCT, French Cooperative Thoracic Intergroup.